MRKR Marker Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1094038 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.7%
TTM net income YoY14.8%
TTM EPS YoY58.3%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-365.9%
Net margin-275.9%
FCF margin—
EBITDA margin—
Returns
ROE-77.0%
ROA-63.3%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets20.9%
Debt / equity0.00x
Current ratio4.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $751,691 | $1.10M | $1.23M | $861,184 | $349,104 | $2.25M |
| R&D expense | $2.17M | $1.48M | $2.84M | $2.14M | $2.35M | $4.18M | $3.14M | $5.09M |
| SG&A expense | $1.06M | $1.14M | $1.23M | $846,606 | $1.02M | $945,163 | $1.37M | $1.03M |
| Operating income | -$3.23M | -$2.62M | -$4.07M | -$1.88M | -$3.37M | -$5.12M | -$4.96M | -$3.86M |
| Net income | -$1.84M | -$1.83M | -$3.18M | -$1.70M | -$2.00M | -$4.02M | -$4.45M | -$3.84M |
| EPS (basic) | -0.10 | -0.09 | -0.16 | — | -0.12 | -0.29 | -0.40 | — |
| EPS (diluted) | -0.10 | -0.09 | -0.16 | — | -0.12 | -0.29 | -0.40 | — |
| Weighted avg. shares (diluted) | 19.31M | 19.31M | 19.31M | — | 16.76M | 13.96M | 11.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.04M | $11.33M | $14.92M | $16.07M | $18.94M | $11.81M | $13.69M | $19.19M |
| Current assets | $12.50M | $14.59M | $17.43M | $19.07M | $21.73M | $14.77M | $16.99M | $22.02M |
| Total assets | $12.50M | $14.59M | $17.43M | $19.07M | $21.73M | $14.77M | $16.99M | $22.02M |
| Current liabilities | $2.00M | $2.42M | $3.64M | $2.27M | $3.35M | $4.28M | $2.50M | $3.46M |
| Total liabilities | $2.00M | $2.42M | $3.64M | $2.27M | $3.35M | $4.28M | $2.50M | $3.46M |
| Shareholders' equity | $10.50M | $12.17M | $13.80M | $16.80M | $18.39M | $10.49M | $14.49M | $18.56M |
| Shares outstanding | 16.70M | 16.70M | 16.70M | 16.70M | 16.70M | 11.30M | 11.20M | 10.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.49M | -$3.72M | -$1.40M | -$1.90M | -$2.74M | -$1.88M | -$5.50M | -$4.70M |
| Financing cash flow | — | — | — | $0 | $9.86M | $100 | $505 | $14.90M |
| Stock-based compensation | $181,887 | $195,735 | $178,422 | $111,131 | $33,279 | $13,986 | $379,144 | $50,544 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.